PTO/SD/17 (12-04v2)
Approved for use through 07/31/2008, OA1B 0651-0052
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2006 (H.R. 4818).	<u></u>	wn .					
	Application Number	10/092.088					
FEE TRANSMITTAL	Filing Date	March 6, 2002					
for FY 2005	First Named Inventor	Audice et al.					
Applicant claims small entity status. See 37 CFR 1.27	Examiner Name	David Lukton					
	Art Unit	1653					
TOTAL AMOUNT OF PAYMENT (\$) 260	Altomey Docket No.	P-022-RC1					
METHOD OF PAYMENT (check all that apply)							
☐ Check ☐ Credit Card ☐ Moncy Order ☐ None ☐ Other (please identify) :							
Deposit Account Deposit Account Number: 50-0344	Deposit Acco	ount Name: Theravance	, Inc.				
For the above-identified deposit account, the Director is	s hereby authorized to:	(check all that apply)					
Charge fee(s) indicated below	☐ Char	ge fee(s) indicated belo	w, except for the filing fee				
Charge any additional fee(s) or underpayments of	of fee(s) 🛛 Cred	it any overpayments					
Under 37 CFR 1.16 and 1.17 WARNING: Information on this form may become public. Credit card to		e included on this form D	rovide credit card				
WARNING: Information on this form may become public. Cream care to information and authorization on PTO-2038.	unormation another flot a	o moreopa on the point. F	101.00 00011 000				
FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES	S ·						
Filing Fees Se	EARCH FEES	EXAMINATION					
Small Entity Application Type Fee (\$) Fee(\$) Fee	Small Entite e(\$) Fee(\$)	<u> </u>	Entity e(\$) Fees Paid (\$)				
Application Type Fee (\$) Fee(\$) Fee(\$)		200 100					
		130 65	,				
Design 200 100 10 Plant 200 100 30		160 80	· —				
Reissue 300 150 50		600 300	· , —				
1	0 0	0 (· , —				
2. EXCESS CLAIM FEES	•		Small Entity				
Fee Description		F	ee (\$) Fee (\$)				
Each claim over 20 (including Reissues)		_	50 25				
Each independent claim over 30 (including Reissues)			100				
Multiple dependent claims		-	180				
Total Claims Extra Claims Fee(\$)	Fee Paid (\$)	7	Multiple Dependent Claim				
20 or HP= × :	= 		Fee (\$) Fee Paid (
HP = highest number of total claims paid for, if greater than 20.	Eas Date /6\						
Indep. Claims	Fee Paid (\$)		:				
- 3 or HP= X HP = highest number of independent claims peid for, if greater than	- <u></u>		•				
I	₩.		!				
3. APPLICATION SIZE FEE This condition and drawings exceed 100 sheets of paper (c	excluding electronical	v filed sequence or com	imiter				
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50							
sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets Extra Sheets Number of ea	ich additional 50 or	fraction thereof F	ee (\$) Fee Paid (\$)				
100 = / 50 = (round up to a whole number) x							
4. OTHER FEE(S)							
Non-English Specification, \$130 fee (no small entity discount)							
Other (e.g., late filing surcharge): Statutory Disclaimer 2@\$130 each							
SUBMITTED BY	Ch Background his						
Signature Self-A-Throng	Registration No. (Allomey/Agent)	35,175	Telephone (650) 808-840				
Name (Print/Type) Jeffrey A. Hagenah			Date January . 20				

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentisity is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 infinites to complote, including gathering, preparing, and submitting the comploted application form to the USPTO. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete this form and/or adoptions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Tondamark Office, U.S. Dependent of Commence, P.O. Box 1450, Alexandrio, VA 22313-1450. ON NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, oall 1-800-PTO-9199 (1-800-786-9199) and scioci option 2.

PTO/S028 (09-04)
Approved for use through 07/31/2008 (09-05)
U.S. Patent and Trademark Office; U.S. DEP/RETMENT OF COMMERCE
Under the Paparwork Reduction Act of 16/05, no persons are required to respond to a catestion of information unless it displays a volid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING Docket Number (Optional) P-022-RC1 **REJECTION OVER A "PRIOR" PATENT** In re Application of: Judice et at. Application No. 10/092,088 Filed: March 6, 2002 For: GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME The owner, Theravance, Inc., of 100 percent interest in the instant application hereby discialms, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent No. <u>U.S. 6.444.786</u> as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee its successors or In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent expires for failure to pay a maintenance fee; is held unenforceable: is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. 1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. 2. The undersigned is an attorney of record. Reg. No. 35,175 January 4 2005 Jeffrey A. Hagenah Typed or printed name (850) 808-6406 Telephone Number Terminal disclaimer fee under 37 CFR 1.20(d) is included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. *Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/98 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officar, U.S. Patent and Trademerk Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 2213-1450. BO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA22313-14\$0.

If you need assistance in completing the form, call 1-800-PTO-9199 and eslect option 2.

PTO: S8/26 (09-04)
Approved for use through 07/31/2006, OAI3 (651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unloss it displays a visid O(18 control number.

Docket Number (Optional) TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING P-022-RG1 **REJECTION OVER A "PRIOR" PATENT** In re Application of: Judice et al. Application No. 10/092,088 Filed: March 6, 2002 For GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME The owner*, <u>Theravence, inc.</u>, of <u>100</u> percent interest in the instant application hereby disctalms, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent No. <u>U.S. 6.620.781</u> as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statuting term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; Is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. 1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the tike so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. 2. The undersigned is an attorney of record. Reg. No. 35,175 January 4, 2005 Jeffrey A. Hagenah Typed or printed name (650) 808-6406 Telephone Number Terminal disclaimer fee under 37 CFR 1.20(d) is included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. *Statement under 37 CFR 3.73(b) is required If terminal discialmer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of Information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, shiuld be sent to the Chief Information Officer, U.S. Patent and Tredemark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA22313-1450.

If you need assistance in completing the form, call 1-800-PTO-8199 and select option 2.



Name/Number: 10092088

Total Records Found: 4

Start Date: Any Date

End Date: Any Date

Accounting Date	Sequence Num.	Tran Type	Fee Code	Fee Amount Mailroom Date	Payment Method
03/13/2002	00000162	1	201	\$370.00 03/06/2002	DA 500344
03/13/2002	00000163	1	<u>203</u>	\$36.00 03/06/2002	DA 500344
03/13/2002	00000164	<u>1</u>	204	\$140.00 03/06/2002	DA 500344
01/14/2005	00000002	<u>1</u>	<u>1814</u>	\$260.00 01/04/2005	DA 500344